^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G13A

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    7ms
    Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases. (PubMed, ESMO Open)
    In patients with CRC PM, different KRAS mutation subgroups can be determined according to specific codon substitution, with some mutations (KRASMUT1) that could have a similar prognosis to wild-type patients. These findings should be further investigated in larger series.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS wild-type • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G12S • KRAS Q61H • KRAS A146T • KRAS A146V • KRAS G13A • KRAS G13C
    1year
    Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer. (PubMed, Genes (Basel))
    These findings imply the genetic basis of KRAS with immunotherapeutic target molecules based on a real-time platform. This study also suggests the highly heterogeneous nature of cancer cells, which may facilitate the assessment of clonal dynamics across a single patient's disease.
    Journal • Circulating tumor cells • IO biomarker • Tumor cell
    |
    KRAS (KRAS proto-oncogene GTPase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    KRAS mutation • KRAS G12D • KRAS G12V • KRAS wild-type • KRAS G12A • KRAS G12 • KRAS G12S • CTLA4 expression • KRAS G13A • KRAS expression
    over1year
    Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer (AACR 2023)
    The combination of avutometinib and everolimus overcomes the activation of the PI3K/AKT/mTOR pathway which is an adaptive resistance mechanism to MAPK pathway inhibition. We have shown that avutometinib and everolimus induce synergistic anti-tumor effects preclinically, and preliminary data suggest clinically meaningful ORR and PFS in patients with KRAS mt NSCLC including non-G12C variants.
    Preclinical • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase) • RPS6 (Ribosomal Protein S6) • AKT1S1 (AKT1 Substrate 1)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS Q61H • KRAS G13A • KRAS G12C + KRAS G12V
    |
    everolimus • avutometinib (VS-6766)
    almost2years
    Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients. (PubMed, Asian Pac J Cancer Prev)
    RAS mutations could be useful in future target anti-EGFR therapy and molecular CRC screening strategy in Morocco.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS wild-type • RAS mutation • NRAS Q61 • KRAS G12S • NRAS Q61R • KRAS Q61H • KRAS exon 2 mutation • NRAS G12D • NRAS G13 • NRAS Q61L • KRAS G13A • KRAS Q61L • NRAS G12S
    over2years
    Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants. (ASCO 2022)
    A tolerable intermittent dosing schedule targeting both the MAPK and PI3K pathways has been established. The combination of VS-6766 with everolimus has shown activity in patients with a variety of KRAS mutation variants including responses in KRAS mt NSCLC.
    P1 data • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • KRAS G12D • KRAS G12V • NRAS Q61K • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12D • NRAS G13 • KRAS G13A • KRAS Q61K
    |
    everolimus • avutometinib (VS-6766)